Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADIL Stock Price Chart Interactive Chart >
ADIL Price/Volume Stats
| Current price | $1.20 | 52-week high | $5.08 |
| Prev. close | $1.34 | 52-week low | $1.04 |
| Day low | $1.19 | Volume | 274,800 |
| Day high | $1.34 | Avg. volume | 161,329 |
| 50-day MA | $1.35 | Dividend yield | N/A |
| 200-day MA | $2.38 | Market Cap | 28.55M |
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about Adial Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderCHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the final patient has completed the last dose and last clinical visit in the Company’s ongoing ONWARD™ Phase 3 trial. ONWARD is evaluating the efficacy, safety and tolerability of AD04 as a therapeutic |
Adial Pharmaceuticals Announces Closing of $10 Million FinancingCHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of the Company’s common stock and pre-funded warran |
Adial Pharmaceuticals announces $10M registered direct offeringAdial Pharmaceuticals (ADIL) will sell 4.2M shares to a single institutional investor worth ~$10M in a registered direct offering and issue warrants in a concurrent private… |
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct OfferingCHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10 million of its common stock (or pre-funded warrants in lieu thereof) in a register |
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate''s PNV-5032 as a Potential Treatment for AsthmaCHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company") , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model. PNV-5032 Relevant Information Greater than 1000-fold selective over the adenosine A1 receptor in potency assays Demonstrated solubility more than 100 times greater than other selective adenosine compounds of the same class currently known to the Company Solubility of an inhaled product allows dissolution in the aerosolized mist for fine distribution over the bronchioles and can be i... |
ADIL Price Returns
| 1-mo | -13.67% |
| 3-mo | -40.89% |
| 6-mo | -56.52% |
| 1-year | -59.18% |
| 3-year | -32.96% |
| 5-year | N/A |
| YTD | -55.56% |
| 2021 | 58.82% |
| 2020 | -29.46% |
| 2019 | -52.93% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...